Traditional Chinese medicine composition for treating ischemic heart failure and preparation method thereof

By regulating multiple signaling pathways through a combination of traditional Chinese medicines such as cinnamon twig, the treatment challenge of ischemic heart failure has been solved, achieving the effects of improving cardiac function, reducing inflammation and myocardial damage, and providing a new treatment strategy.

CN121513154AActive Publication Date: 2026-02-13FIRST PEOPLES HOSPITAL OF YUNNAN PROVINCE
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202610055742.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-01-16
Publication Date
2026-02-13
Estimated Expiration
2046-01-16

AI Technical Summary

Technical Problem

Treatment of ischemic heart failure faces high risks of revascularization, poor drug efficacy, and high risk of cardiovascular events, and lacks effective intervention strategies targeting key pathological aspects such as inflammation.

Method used

A traditional Chinese medicine composition consisting of cinnamon twig, atractylodes macrocephala, poria cocos, dried ginger, eleutherococcus senticosus, water lily seed, verbena, cornus officinalis, and prepared licorice root is provided. It is prepared into granules, tablets, capsules, or oral liquids through specific proportions and processing methods. It exerts the effects of warming yang, promoting diuresis, activating blood circulation, and tonifying the kidneys, and regulates multiple signaling pathways to improve cardiac function.

Benefits of technology

It significantly reduces N-terminal pro-B-type natriuretic peptide levels, improves cardiac function, reduces myocardial damage and inflammation, and regulates myocardial fibrosis. It has multi-target and multi-pathway therapeutic effects and good safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121513154A_ABST
    Figure CN121513154A_ABST
Patent Text Reader

Abstract

The invention relates to a traditional Chinese medicine composition for treating ischemic heart failure and a preparation method thereof, and belongs to the field of traditional Chinese medicine pharmacy, and the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 5-15 parts of cassia twig, 5-15 parts of bighead atractylodes rhizome, 5-15 parts of poria cocos, 6-12 parts of rhizoma zingiberis, 5-15 parts of acanthopanax, 10-30 parts of fructus polygoni orientalis, 3-9 parts of verbena, 6-12 parts of dogwood and 3-9 parts of honey-fried licorice root. The composition can remarkably reduce the level of N-terminal proB-type natriuretic peptide, remarkably improve pathological changes of heart tissues of model rats, regulate and control the heart functions of the model rats, improve the systolic function of the heart, relieve expression of inflammatory factors such as interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha of the rats and improve the anti-inflammatory effect of the rats. The action mechanism of the compound relates to a plurality of pathways such as extracellular matrix receptor interaction, a chemotactic factor signal pathway, a relaxin signal pathway, a cyclic adenosine monophosphate signal pathway, a nuclear factor-kB signal pathway, fatty acid metabolism and a Toll-like receptor signal pathway, and the compound is an effective medicament for treating ischemic heart failure.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine pharmaceutical technology, and to a traditional Chinese medicine composition for treating heart failure, particularly a traditional Chinese medicine composition for treating ischemic heart failure and its preparation method. Background Technology

[0002] Heart failure is one of the major public health problems worldwide. According to data from the Global Burden of Disease Study, the number of people with heart failure globally increased significantly from 25.4 million in 1990 to 55.5 million in 2021. The "China Cardiovascular Health and Disease Report 2023" estimates that there are approximately 8.9 million heart failure patients in China. With improved living standards, the etiology of heart failure in China has changed significantly, with ischemic heart disease replacing rheumatic heart disease as the most common cause. Compared to non-ischemic heart failure, ischemic heart failure carries a higher risk of cardiovascular events and death, thus becoming a pressing clinical challenge.

[0003] Currently, the main treatment strategies for ischemic heart disease remain focused on revascularization and drug therapy. Revascularization can restore the contractile function of stunned or hibernating myocardium in some patients by improving myocardial perfusion. However, the pathogenesis of myocardial ischemia is not solely caused by coronary artery stenosis; it is also closely related to various pathological factors such as coronary artery spasm, coronary microcirculatory disturbances, persistent inflammatory response, platelet and coagulation dysfunction, and vascular endothelial dysfunction. Numerous studies have shown that chronic low-grade inflammation plays a crucial role in the progression of ischemic heart disease and its progression to heart failure. It can not only exacerbate cardiomyocyte damage and fibrosis but also promote ventricular remodeling and continuous deterioration of cardiac function through excessive interaction with the neuroendocrine system. Theoretically, early revascularization can improve resting blood flow and coronary blood flow reserve, salvaging hibernating myocardium and thus preventing or reversing ventricular remodeling. However, in patients with ischemic heart failure, due to severely impaired cardiac function and extensive and complex coronary artery lesions, the risks of revascularization-related surgeries are significantly increased, and its long-term prognostic benefits remain controversial. On the other hand, while drug therapy can slow disease progression by inhibiting neuroendocrine activation and improving hemodynamic status, even when the maximum tolerated dose of the guideline-recommended drugs is reached, patients still face a high risk of cardiovascular events, and some patients experience poor efficacy or tolerability. Therefore, the prevention and treatment of ischemic heart failure still face severe challenges, and there is an urgent need for new intervention strategies or therapeutic drugs targeting key pathological aspects such as inflammation, in order to improve disease outcomes from a multi-target perspective. Summary of the Invention

[0004] Based on the above objectives, this application, leveraging the advantages of traditional Chinese medicine in treating ischemic heart failure—namely, its definite efficacy, minimal side effects, and its ability to compensate for the shortcomings of Western medicine—provides a traditional Chinese medicine composition for treating ischemic heart failure and its preparation method therein, offering a new option for clinical treatment. The specific technical solution is as follows:

[0005] The first objective of this invention is to provide a traditional Chinese medicine composition for treating ischemic heart failure, which is made from the following raw materials in parts by weight: 5-15 parts of cinnamon twig, 5-15 parts of atractylodes macrocephala, 5-15 parts of poria cocos, 6-12 parts of dried ginger, 5-15 parts of eleutherococcus senticosus, 10-30 parts of safflower seed, 3-9 parts of verbena, 6-12 parts of cornus officinalis, and 3-9 parts of prepared licorice root.

[0006] Furthermore, the traditional Chinese medicine composition is made from the following raw materials in parts by weight: 10 parts cinnamon twig, 10 parts atractylodes macrocephala, 10 parts poria cocos, 9 parts dried ginger, 10 parts eleutherococcus senticosus, 15 parts water lily seeds, 6 parts verbena, 9 parts cornus officinalis, and 6 parts prepared licorice root.

[0007] A second objective of this invention is to provide a method for preparing a traditional Chinese medicine composition for treating ischemic heart failure, comprising the following steps:

[0008] Step 1: Weigh out each Chinese medicinal herb as raw material according to the prescription ratio;

[0009] Step 2: Soak the herbs in 10-15 times their volume of water for 30-60 minutes, based on the amount of herbs taken in Step 1.

[0010] Step 3: Boil the soaked herbs twice, filter the liquids separately, and combine them.

[0011] Step 4: Concentrate the combined decoction to obtain a medicinal paste;

[0012] Step 5: Further process the obtained liquid medicine to prepare the desired dosage form.

[0013] Furthermore, in step 3, the decoction method is to first bring it to a boil over high heat, then simmer it over low heat for 60 minutes, and filter it to obtain the first decoction. After the decoction is completed, the liquid and the dregs are separated. The dregs are then added to 8 times the amount of water, brought to a boil over high heat, then simmered over low heat for 30 minutes, and filtered to obtain the second decoction. The filtered decoctions are then combined.

[0014] Furthermore, the further processing in step 5 includes: obtaining dry powder or extract powder by vacuum concentration, spray drying or freeze drying.

[0015] Furthermore, the dosage form of a traditional Chinese medicine composition for treating ischemic heart failure includes adding excipients, mixing, granulating or compressing to form granules or tablets, and filling the resulting powder or granules into empty capsules to prepare capsules; sterilizing the clarified medicinal liquid and dispensing it to prepare oral liquid; or adding a suitable binder to form water pills, honey pills or ointments.

[0016] Working principle of the invention:

[0017] Cinnamon twig: This product is the dried tender twig of *Cinnamomum cassia* Presl, a plant in the Lauraceae family. It is pungent, sweet, and warm in nature. It enters the heart, lung, and bladder meridians. It has the effects of inducing sweating and relieving muscle tension, warming and unblocking the meridians, assisting yang and promoting qi circulation, and calming and descending qi. Modern pharmacological studies have shown that cinnamon twig contains volatile oils (cinnamaldehyde, cinnamic acid, cinnamyl alcohol), flavonoids (quercetin, kaempferol), polysaccharides, coumarins, and other components. Cinnamaldehyde can dilate coronary arteries, reduce peripheral resistance, and improve myocardial microcirculation; inhibit platelet aggregation and reduce blood viscosity; and has antioxidant properties, reducing the generation of oxygen free radicals and alleviating ventricular remodeling.

[0018] Atractylodes macrocephala: This product is the dried rhizome of Atractylodes macrocephala Koidz., a plant of the Asteraceae family. It is bitter, sweet, and warm in nature. It enters the spleen and stomach meridians. It has the effects of strengthening the spleen and replenishing qi, drying dampness and promoting diuresis, stopping sweating, and calming the fetus. Modern pharmacological studies have shown that Atractylodes macrocephala mainly contains sesquiterpene lactones (atractylodes lactone, atractylodes lancea lactone), polysaccharides, flavonoids, and other components. Atractylodes macrocephala polysaccharides can enhance the antioxidant capacity of myocardial cells; atractylodes lactones II and III can reduce inflammatory cell infiltration in myocardial tissue after myocardial infarction and inhibit platelet activation and myocardial fibrosis.

[0019] Poria cocos: This product is the dried sclerotium of the fungus Poria cocos (Schw.) Wolf, belonging to the Polyporaceae family. It is sweet, bland, and neutral in nature. It enters the heart, lung, spleen, and kidney meridians. It has the effects of promoting diuresis and eliminating dampness, strengthening the spleen, and calming the mind. Modern pharmacological studies have shown that Poria cocos contains triterpenoids (pachymic acid, pachymic acid), Poria cocos polysaccharides, sterols, and other components. Poria cocos polysaccharides have diuretic, immunomodulatory, and antioxidant effects. Triterpenoids can block the renin-angiotensin-aldosterone system, reduce angiotensin II levels, alleviate ventricular remodeling, and have anti-inflammatory effects, offering protection against ischemic heart failure.

[0020] Dried ginger: This product is the dried rhizome of ginger (Zingiber officinale Rosc.), a plant in the ginger family. It is pungent and hot in nature. It enters the spleen, stomach, kidney, heart, and lung meridians. It has the effects of warming the middle jiao and dispelling cold, restoring yang and unblocking the meridians, and warming the lungs and resolving phlegm. Modern pharmacological studies have shown that dried ginger mainly contains gingerol (6-gingerol, 8-gingerol, 10-gingerol), shogaol, flavonoids, volatile oils, and other components. 6-Gingerol can improve myocardial energy metabolism by increasing the activity of sarcoplasmic reticulum / endoplasmic reticulum calcium ion ATPase, inhibiting the nuclear factor-κB pathway, and reducing myocardial inflammatory response. In ischemic heart failure, the active ingredients of dried ginger can also reduce myocardial oxidative stress and improve cardiac function.

[0021] Acanthopanax senticosus: This product is the dried root and rhizome or stem of Acanthopanax senticosus (Rupr. et Maxim.) Harms, a plant of the Araliaceae family. It is pungent, slightly bitter, and warm in nature. It enters the spleen, kidney, and heart meridians. It has the effects of invigorating qi and strengthening the spleen, tonifying the kidneys and calming the mind. Modern pharmacological studies have shown that Acanthopanax senticosus contains flavonoids, organic acids, lignans, coumarins, etc. Among them, eleutheroscinoside B reduces cardiomyocyte necrosis and apoptosis and improves myocardial injury through the nuclear factor-erythrocyte kinase 2-related factor 2 / heme oxygenase-1 signaling pathway. Clinical studies have shown that Acanthopanax senticosus can improve left ventricular diastolic function in patients with angina pectoris, and has the effects of dilating coronary arteries, increasing coronary blood flow, slowing heart rate, and inhibiting myocardial contractility.

[0022] Verbena officinalis: This product is the dried aerial part of the plant Verbena officinalis L., belonging to the Verbenaceae family. It is bitter and cool in nature. It enters the liver and spleen meridians. It has the effects of promoting blood circulation and removing blood stasis, detoxifying, promoting diuresis, reducing jaundice, and treating malaria. Modern pharmacological studies have shown that Verbena officinalis mainly contains iridoid glycosides (verbenosinoside, harbazoside), flavonoids (luteolin, apigenin), phenylethyl glycosides, etc. Verbenosinoside can inhibit platelet activation and aggregation, improve coronary microcirculation, and reduce the degree of myocardial ischemia; ursolic acid can inhibit the transforming growth factor-β signaling pathway, reduce myocardial collagen deposition, and delay the progression of myocardial fibrosis.

[0023] Water Polygonum Orientale L.: This product is the dried, mature fruit of the Polygonaceae plant *Polygonum orientale* L. It is salty and slightly cold in nature. It enters the Liver and Stomach meridians. It has the effects of dispersing blood stasis and eliminating masses, relieving pain, and promoting diuresis and reducing swelling. Modern pharmacological studies have shown that Water Polygonum Orientale L. contains flavonoids (such as quercetin, fentanyl, and fentanyl), amides (such as p-coumaryltyramine and p-feruloyltyramine), and alkaloids. Quercetin and quercetin can reduce lipid peroxidation, improve myocardial ischemia and hypoxia, and inhibit myocardial cell apoptosis.

[0024] Cornus officinalis: This product is the dried, ripe pulp of the plant Cornus officinalis Sieb. et Zucc. (family Cornaceae). It is sour, astringent, and slightly warm in nature. It enters the liver and kidney meridians. It has the effects of tonifying the liver and kidneys, and astringing and consolidating. Modern pharmacological studies have shown that Cornus officinalis contains iridoid glycosides (loganin, loganic acid), organic acids, flavonoids, polysaccharides, and other components. Loganic acid can scavenge oxygen free radicals and restore mitochondrial respiratory function to improve cardiac remodeling after myocardial infarction and delay the occurrence and development of heart failure.

[0025] Prepared licorice root: Licorice is the dried root and rhizome of Glycyrrhiza uralensis Fisch., Glycyrrhiza inflata Bat., or Glycyrrhiza glabra L., all belonging to the legume family. This product is a processed form of licorice root. Licorice slices are prepared using the honey-processing method (stir-frying until yellow to dark yellow, no longer sticky, then removing and cooling). It is sweet and neutral in nature. It enters the heart, lung, spleen, and stomach meridians. It has the effects of tonifying the spleen and stomach, replenishing qi and restoring pulse. Modern pharmacological studies have shown that prepared licorice root contains triterpenoid saponins (glycyrrhizic acid, 18β-glycyrrhetinic acid), flavonoids (glycyrrhizin, isoglycyrrhizin), polysaccharides, and other components. Glycyrrhizic acid and its metabolites can regulate potassium channel currents, improve myocardial electrical activity, and reduce the incidence of arrhythmias. Glycyrrhetinic acid improves cardiac function by upregulating the nuclear factor-erythrocyte kinase 2-related factor 2 / heme oxygenase 1 signaling pathway, inhibiting oxidative stress, apoptosis, and regulating mitochondrial function.

[0026] The formulation principle is as follows: dried ginger and cinnamon twig are the principal herbs; atractylodes macrocephala and poria cocos are the assistant herbs; eleutherococcus senticosus, verbena, hemp seed, and cornus officinalis are the adjuvant herbs; and prepared licorice root is the guiding herb. The nine components work synergistically, providing warmth without causing dryness, promoting diuresis without harming the body, dispersing while astringing, addressing both the root cause and the symptoms. The composition ratio of this invention is optimized through multiple rounds of orthogonal experiments based on the medicinal properties, efficacy, and synergistic effects of each component: the ratio of dried ginger to cinnamon twig is controlled at 1:1-1.5 to avoid excessive warming and causing dryness, while maximizing the effect of warming and invigorating the heart yang; the ratio of eleutherococcus senticosus to cornus officinalis is 1:1, balancing qi tonification and liver and kidney tonification, avoiding the cloying and stomach-heavy effects of single tonification; the ratio of hemp seed to verbena is 2:1, enhancing the blood-activating and diuretic effects while avoiding the risk of bleeding due to excessive blood activation. The above ratio has been verified through clinical pre-experimentation and is key to achieving 'warming yang without causing dryness, activating blood without harming the body's vital energy, and promoting diuresis without depleting qi'.

[0027] In this formula, dried ginger and cinnamon twig are the principal herbs. Cinnamon twig is pungent and sweet in taste and warm in nature. It enters the heart, lung, and bladder meridians. It can directly tonify heart yang and also "warm and unblock the meridians," guiding other herbs directly to the heart meridian and enhancing the overall targeted effect of the formula on the cardiovascular system. At the same time, dried ginger warms and invigorates spleen yang, providing "acquired foundation" support for heart yang. Its heat can also enhance the warming effect of cinnamon twig on heart yang, improving symptoms such as heart yang deficiency accompanied by aversion to cold, cold hands and feet, pale tongue with white coating.

[0028] Atractylodes macrocephala and Poria cocos are used as assistant herbs: the two are a classic "spleen-strengthening and diuretic" combination (derived from Linggui Zhugan Decoction); Atractylodes macrocephala is sweet and bitter in taste and warm in nature, and enters the spleen and stomach meridians. It can strengthen the spleen and replenish qi, dry dampness and promote diuresis. By tonifying the spleen and strengthening the spleen and stomach, it can improve the internal retention of dampness caused by spleen yang deficiency (dampness overflowing easily ascends to the heart and lungs, aggravating palpitations and shortness of breath, or overflowing to the skin and causing edema), providing the "spleen transportation" basis for "drainage". Poria cocos is sweet and bland in taste and neutral in nature, and enters the heart, lung, spleen and kidney meridians. It can promote diuresis and eliminate dampness, strengthen the spleen and calm the mind. On the one hand, it helps Atractylodes macrocephala enhance its diuretic power and remove excess water in the body (reducing the burden on the cardiovascular system); on the other hand, its "calming the mind" effect can directly improve palpitations and insomnia, forming a synergistic effect of "warming yang + calming the mind" with the "warming heart yang" of cinnamon twig.

[0029] The adjuvant herbs are Acanthopanax senticosus, Cornus officinalis, Polygonum hydropiper, and Verbena officinalis—which invigorate qi and strengthen the kidneys, promote blood circulation and diuresis, taking into account both "concurrent symptoms" and "balance." The adjuvant herbs in this formula are "assistant herbs," which assist the principal and assistant herbs in enhancing the efficacy.

[0030] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0031] Firstly, the herbal composition of this invention does not have a completely corresponding formula. Its formulation approach is similar to the classic formula Linggui Zhugan Decoction in terms of warming yang, resolving phlegm, strengthening the spleen, and promoting diuresis. However, this invention has the following advantages:

[0032] 1. The addition of Acanthopanax senticosus breaks through the limitation of Linggui Zhugan Decoction only warming and tonifying the middle yang. It can warm the spleen yang while also tonifying the kidney qi, so that the formula is not only suitable for water retention due to simple deficiency of middle yang, but also to plant the "fire" of warming yang in the lower jiao and the gate of life, so that the qi transformation of the three jiao has a source.

[0033] 2. The combination of verbena and water lily seeds adds the properties of promoting blood circulation and diuresis to the formula. The combination of the two can remove blood stasis while promoting diuresis, which solves the shortcoming of Linggui Zhugan Decoction that "only promotes diuresis but does not remove blood stasis". It is more suitable for improving water and sodium retention in patients with ischemic heart failure.

[0034] 3. The addition of Cornus officinalis achieves a balance between tonifying and astringing, and eliminating pathogens without harming the body's vital energy. On the one hand, Cornus officinalis assists Acanthopanax senticosus in enhancing the kidney-tonifying effect. On the other hand, it can restrain the "dissipative nature" of diuretics and blood-activating drugs such as Verbena officinalis and Polygonum hydropiper. This avoids the hidden danger of insufficient Qi and Yin due to long-term use of the classic Linggui Zhugan Decoction, which is solely for diuresis. This reflects the organic extension and clinical upgrade of the classic path by modern TCM.

[0035] 4. Animal experiments have demonstrated that the traditional Chinese medicine composition provided by this invention can significantly reduce the level of N-terminal pro-B natriuretic peptide, significantly improve the pathological changes in the heart tissue of model rats, regulate the heart function of rats, especially improve the contractile function of the heart, and reduce the expression of inflammatory factors such as interleukin-1β, interleukin-6, and tumor necrosis factor α in rats. Its mechanism of action involves multiple pathways such as extracellular matrix receptor interaction, chemokine signaling pathway, relaxin signaling pathway, cyclic adenosine monophosphate signaling pathway, nuclear factor-κB signaling pathway, fatty acid metabolism, and Toll-like receptor signaling pathway, making it an effective agent for the treatment of ischemic heart failure.

[0036] 5. When dried ginger, Acanthopanax senticosus, Polygonum hydropiper, Verbena officinalis and Cornus officinalis are removed from the traditional Chinese medicine composition of the present invention, the regulatory effect of the traditional Chinese medicine composition on heart failure markers and inflammatory factors is significantly weakened. Attached Figure Description

[0037] Figure 1 The results of echocardiography in rats are shown below; (A) representative echocardiographic images of each group; (B) changes in left ventricular ejection fraction (LVEF) in each group; (C) changes in left ventricular fractional shortening (LVFS) in each group. Compared with the blank control (sham-operated group), *P<0.05; **P<0.01; ***P<0.001; compared with the model group, #P<0.05; ##P<0.01; ###P<0.001.

[0038] Figure 2 The results of rat serum factor detection include: (A) N-terminal pro-B-type natriuretic peptide levels in each group; (B) interleukin-1β levels in each group; (C) interleukin-6 levels in each group; and (D) tumor necrosis factor-α levels in each group. Compared with the blank control group, #P<0.05; ##P<0.01; ###P<0.001. Compared with the model group, *P<0.05; **P<0.01; ***P<0.001.

[0039] Figure 3 Staining of rat heart tissue pathological sections; (A) HE staining results for each group, (B) Masson staining results for each group.

[0040] Figure 4The results are as follows: (A) Volcano plot of differentially expressed genes between the model group and the traditional Chinese medicine group; (B) Pathway enrichment analysis of differentially expressed genes between the model group and the traditional Chinese medicine group.

[0041] Figure 5 The results are for liver and kidney function in rats; (A) is the alanine aminotransferase level in each group, (B) is the aspartate aminotransferase level in each group, (C) is the serum creatinine level in each group, and (D) is the serum urea level in each group.

[0042] Figure 6 The study aimed to investigate the regulatory effects of a traditional Chinese medicine composition without the removal of dried ginger, Acanthopanax senticosus, Polygonum hydropiper, Verbena officinalis, and Cornus officinalis on ischemic heart failure. The study included: (A) N-terminal pro-B-type natriuretic peptide levels in each group; (B) interleukin-1β levels in each group; (C) interleukin-6 levels in each group; and (D) tumor necrosis factor-α levels in each group. Compared with the blank control group (sham-operated group), *P < 0.05; **P < 0.01; ***P < 0.001. Compared with the model group, #P < 0.05; ##P < 0.01; ###P < 0.001. Compared with the composition without the removal of dried ginger, Acanthopanax senticosus, Polygonum hydropiper, Verbena officinalis, and Cornus officinalis, +P < 0.05; ++P < 0.01; +++P < 0.001. Detailed Implementation

[0043] The present invention will now be described in further detail with reference to specific embodiments and accompanying drawings.

[0044] Example 1: A method for preparing a traditional Chinese medicine composition for treating ischemic heart failure, comprising the following steps: 10 parts of cinnamon twig, 10 parts of atractylodes macrocephala, 10 parts of poria cocos, 9 parts of dried ginger, 10 parts of eleutherococcus senticosus, 15 parts of water lily seeds, 6 parts of verbena, 9 parts of cornus officinalis, and 6 parts of prepared licorice root are soaked in 700ml of water for 30 minutes; after boiling over high heat, the decoction is simmered over low heat for 60 minutes, and filtered to obtain the first decoction; after decoction, the liquid and dregs are separated, and the dregs are added to 8 times the amount of water, boiled over high heat, and simmered over low heat for 30 minutes, and filtered to obtain the second decoction; the filtrates are combined. After further adding conventional granulation excipients and sterilizing, granules are prepared according to conventional methods.

[0045] Example 2: A method for preparing a traditional Chinese medicine composition for treating ischemic heart failure, comprising the following steps: 5 parts of cinnamon twig, 5 parts of atractylodes macrocephala, 5 parts of poria cocos, 6 parts of dried ginger, 5 parts of eleutherococcus senticosus, 10 parts of water lily seeds, 3 parts of verbena, 6 parts of cornus officinalis, and 3 parts of prepared licorice root are soaked in 700ml of water for 30 minutes; after boiling over high heat, the decoction is simmered for 60 minutes, and filtered to obtain the first decoction; after decoction, the liquid and dregs are separated, and the dregs are added to 10 times the amount of water, boiled over high heat, simmered for 30 minutes, and filtered to obtain the second decoction; the filtrates are combined. After further adding conventional granulation excipients and sterilizing, granules are prepared according to conventional methods.

[0046] Example 3: A method for preparing a traditional Chinese medicine composition for treating ischemic heart failure, comprising the following steps: 15 parts of cinnamon twig, 15 parts of atractylodes macrocephala, 15 parts of poria cocos, 12 parts of dried ginger, 15 parts of eleutherococcus senticosus, 30 parts of water lily seeds, 9 parts of verbena, 12 parts of cornus officinalis, and 9 parts of prepared licorice root are soaked in 1000ml of water for 30 minutes; after boiling over high heat, the decoction is simmered for 60 minutes, and filtered to obtain the first decoction; after decoction, the liquid and dregs are separated, and the dregs are added to 15 times the amount of water, boiled over high heat, simmered for 30 minutes, and filtered to obtain the second decoction; the decoction is repeated 4 times and the filtrates are combined. After further adding conventional granulation excipients and sterilizing, granules are prepared according to conventional methods.

[0047] Experimental Example 1: Animal Pharmacology Experiment (using the drug composition of Example 1)

[0048] 1. Materials and Methods

[0049] Animal studies using the traditional Chinese medicine composition of Example 1

[0050] Eighty-five specific pathogen-free (SPF) grade male SD rats, weighing 200 ± 20 g, were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. The rats were given a free-range standard synthetic diet and purified water, and were housed under the following conditions: temperature (24℃ ± 2℃), humidity (45%-50%), and 12-hour alternating day and night light. A rat model of myocardial infarction was established by skilled personnel through ligation of the left anterior descending artery. In short, the rats were anesthetized with isoflurane ventilation, fixed in a supine position on the dissection table, and their fur was clipped, skin prepared, and disinfected. A ventilator was inserted (tidal volume 3 ml / 100 g body weight, respiratory rate 60 breaths / min). The ribs were separated to expose the heart, and a surgical suture was used to ligate the heart 2-3 mm below the left atrial appendage. Successful ligation was confirmed by electrocardiogram examination (such as ST segment elevation) and immediate pallor of the ligation area. In the sham-operated group, only suture was threaded; arterial ligation was not performed. After successful establishment of the myocardial infarction model, rats were fed normally for one week, followed by echocardiography. A left ventricular ejection fraction (LVEF) <50% was considered a successful model of ischemic heart failure. The rats were randomly divided into six groups using a random number table: sham-operated group, model group, low-dose group of the traditional Chinese medicine composition (3.75 g / kg / d), medium-dose group of the traditional Chinese medicine composition (7.5 g / kg / d), high-dose group of the traditional Chinese medicine composition (15 g / kg / d), and enalapril group (0.45 mg / kg / d). Treatment continued for 28 days. Animal dosages were converted to human dosages based on body surface area and weight. Rats in the Sham and Model groups were administered an equal volume of phosphate buffer solution by gavage.

[0051] 2. Echocardiography

[0052] Anesthetized rats were examined for cardiac function using two-dimensional M-mode and B-mode echocardiography by technicians unaware of their grouping. The results are as follows: Figure 1 As shown:

[0053] Figure 1 A (Echocardiography): In the sham surgery group, myocardial motion showed regular waveforms, with coordinated ventricular wall contraction and relaxation; in the model group, myocardial waveforms were disordered, and ventricular wall motion was abnormal, indicating impaired cardiac function; the myocardial waveforms in different treatment groups and the enalapril group (positive control group, angiotensin-converting enzyme inhibitor) gradually improved compared to the model group.

[0054] Figure 1 B (Left ventricular ejection fraction, LVEF): The sham surgery group had a higher LVEF value (approximately 80% or more); the model group had a significantly lower LVEF. (# indicates a highly significant difference compared to the sham surgery group); the increased LVEF in the medium-dose and high-dose groups was significantly greater than that in the model group (# and ## indicate significant or highly significant differences compared to the model group), indicating that the treatment can improve left ventricular ejection function.

[0055] Figure 1 C (short axis shortening rate, FS): The FS value was higher in the sham surgery group (approximately 50%); the FS value was significantly lower in the model group. The difference is extremely significant compared to the Sham group; the FS of medium and high doses is significantly higher than that of the model group (# and ## indicate significant or extremely significant differences compared to the model group).

[0056] In summary, compared with the blank control group, the model group rats showed changes in cardiac structure, with decreased left ventricular ejection fraction (LVEF) and fractional shortening (FS). Treatment with different doses of traditional Chinese medicine (TCM) significantly increased LVEF and FS (P < 0.05). These results indicate that the model group successfully established a cardiac dysfunction model. Treatment with different doses of the TCM composition (especially medium and high doses) improved myocardial motor function, increased LVEF and FS, thereby improving cardiac function and enhancing cardiac contractility. This further demonstrates that the TCM composition has a protective effect on the heart and can provide experimental evidence for the treatment or intervention of related cardiac diseases.

[0057] 3. Serological testing

[0058] Blood was collected from the abdominal aorta of rats after anesthesia. After standing at room temperature for 1 hour, the blood was centrifuged at 3000 rpm for 10 minutes at 4°C. The levels of N-terminal pro-B-type natriuretic peptide, interleukin-1β, interleukin-6, and tumor necrosis factor-α were detected using enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions. The results are as follows: Figure 2 As shown:

[0059] Figure 2A (N-terminal pro-B-type natriuretic peptide, NT-proBNP level): The NT-proBNP level was lower in the Sham group (sham surgery group); the NT-proBNP level was significantly higher in the model group. (#, ##, ### indicate significant or highly significant differences compared to the Sham group); the NT-proBNP levels in the low-dose group, medium-dose group, high-dose group, and enalapril (positive control group) were significantly lower than those in the model group, and the decrease was more significant in the medium-dose, high-dose, and enalapril groups (#, ##, ### indicate significant or highly significant differences compared to the model group).

[0060] Figure 2 B (Interleukin-1β, IL-1β levels): The Sham group had lower IL-1β levels; the model group had significantly higher IL-1β levels. (#, ##, ### indicate a highly significant difference compared to the Sham group); IL-1β levels in different dose groups and the enalapril group were significantly lower than those in the model group (#, ##, ### indicate significant or highly significant differences compared to the model group).

[0061] Figure 2 C (Interleukin-6, IL-6 level): The Sham group had lower IL-6 levels; the model group had significantly higher IL-6 levels. (# indicates a highly significant difference compared to the Sham group); the IL-6 levels in the different dose groups of traditional Chinese medicine and the enalapril group were lower than those in the model group, with the reduction being more significant in the medium-dose, high-dose, and enalapril groups (#, ##, ### indicate significant or highly significant differences compared to the model group).

[0062] Figure 2 D (Tumor necrosis factor-α, TNF-α levels): The Sham group had lower TNF-α levels; the model group had significantly higher TNF-α levels. (# indicates a highly significant difference compared to the Sham group); the IL-6 levels in the different dose groups of traditional Chinese medicine and the enalapril group were lower than those in the model group, with the reduction being more significant in the medium-dose, high-dose, and enalapril groups (#, ##, ### indicate significant or highly significant differences compared to the model group).

[0063] The above results indicate that, compared with the blank control group, the levels of heart failure markers (N-terminal pro-B-type natriuretic peptide) and inflammatory markers (interleukin-1β, interleukin-6, and tumor necrosis factor-α) in the model group rats were significantly increased. Different doses of treatment (especially medium and high doses) and ACEI treatment could reduce NT-proBNP levels, improve cardiac function-related indicators, and significantly inhibit the expression of inflammatory factors IL-1β, IL-6, and TNF-α, thus alleviating the inflammatory response. This suggests that the traditional Chinese medicine composition of the present invention has an ameliorative effect on heart failure and can reduce cardiac inflammatory markers, thus protecting the heart through anti-inflammatory mechanisms, providing experimental evidence for the treatment or intervention of related heart diseases.

[0064] 4. Staining of cardiac tissue pathological sections

[0065] Rat heart tissue was collected and fixed overnight in 4% paraformaldehyde. It was then embedded in paraffin and sectioned to 4 μm. Hematoxylin-eosin and Masson staining were performed according to the manufacturer's instructions. The results are as follows: Figure 3 As shown: Compared with the blank control group, Figure 3 HE staining results showed that the model group had disordered cardiomyocyte structure, loose arrangement, nucleus condensation or fragmentation, and significant immune infiltration. After traditional Chinese medicine treatment, immune infiltration was reduced, and the integrity of cell structure and arrangement was preserved. Compared with the blank control group, Figure 3 B Masson staining revealed a distinct distribution of blue collagen fibers in the cardiomyocytes of the model group, and the traditional Chinese medicine treatment reduced collagen deposition. This indicates that the traditional Chinese medicine composition of this invention has a protective effect on cardiac tissue.

[0066] The results showed that the model group successfully constructed a model of myocardial injury (possibly accompanied by myocardial fibrosis). Medium and high doses of treatment improved the pathological morphology of myocardial tissue, reduced the degree of myocardial fibrosis, and protected the heart tissue, providing histological experimental evidence for the treatment or intervention of related heart diseases.

[0067] 5. Transcriptomic analysis of the potential mechanisms of action of traditional Chinese medicine compositions

[0068] Left ventricular myocardial tissue was collected from experimental animals, and total RNA was extracted using conventional methods. RNA integrity was assessed by agarose gel electrophoresis, while RNA purity and concentration were determined using a UV spectrophotometer or bioanalyzer. Qualified RNA samples were enriched with mRNA or desorbed with rRNA, then fragmented and reverse transcribed to synthesize cDNA. After end repair, A-tailing, and adapter ligation, sequencing libraries were obtained. After quality control, the libraries were subjected to paired-end sequencing using a high-throughput sequencing platform. The raw sequencing data underwent quality control to remove low-quality reads and adapter sequences, obtaining high-quality clean reads. Clean reads were aligned to reference genome or transcript databases, and gene or transcript expression levels were calculated. Statistical analysis was performed on gene expression levels between different groups based on sample grouping to screen for differentially expressed genes. The criteria for differential screening were an absolute value of the logarithmic fold change > 0.25 and a significance level P-value < 0.05. Pathway enrichment analysis was performed on differentially expressed genes to explore their potential biological functions and signaling pathways. The results are as follows: Figure 4 As shown, 115 significantly altered genes were identified in the model group and the traditional Chinese medicine group. These differentially altered genes were enriched into pathways, mainly involving extracellular matrix receptor interaction, chemokine signaling pathway, relaxin signaling pathway, cyclic adenosine monophosphate signaling pathway, nuclear factor-κB signaling pathway, fatty acid metabolism, and Toll-like receptor signaling pathway. These results indicate that the traditional Chinese medicine composition of this invention has a multi-target, multi-pathway mechanism of action that protects cardiac tissue.

[0069] 6. Safety Indicators

[0070] After appropriate treatment of each group of experimental animals, blood samples were collected. Then, biochemical detection methods were used to detect the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (Scr), and urea (UREA) in the blood.

[0071] The results are as follows Figure 5 The results of liver and kidney function tests showed that, throughout the experiment, no differences were found in liver function indicators such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) among the different doses of the traditional Chinese medicine composition compared to the normal group, and no differences were found in kidney function indicators such as creatinine and urea. This indicates that the traditional Chinese medicine composition of the present invention is safe.

[0072] 7. The regulatory effect of the traditional Chinese medicine composition of the present invention on ischemic heart failure.

[0073] A comparison was made between the formulation of this invention and the existing Linggui Zhugan Decoction, and the results are shown below. Figure 6In all four indicators, the expression levels in the model group were significantly higher than those in the sham-operated group, indicating successful modeling and the animal model exhibiting significant inflammatory response and heart failure-related pathological changes. Furthermore, both the Linggui Zhugan Decoction group (excluding the dried ginger, Acanthopanax senticosus, Polygonum hydropiper, Verbena officinalis, and Cornus officinalis of this invention) and the positive control traditional Chinese medicine significantly reduced indicator levels: compared to the model group, the expression levels of NT-proBNP, IL-1β, IL-6, and TNF-α were significantly reduced in all treatment groups of Linggui Zhugan Decoction (3.2 g / kg, 6.4 g / kg) and the positive control traditional Chinese medicine (7.5 g / kg, 15 g / kg), demonstrating that both drugs effectively improved the inflammatory response and heart failure status. However, it is evident that the intervention effect of Linggui Zhugan Decoction is weaker than that of the traditional Chinese medicine composition of this invention, such as its significantly weakened regulatory effect on heart failure markers (N-terminal pro-B-type natriuretic peptide) and inflammatory factors (interleukin-1β, interleukin-6, and tumor necrosis factor-α levels) (see...). Figure 6 This indicates that the efficacy of the traditional Chinese medicine composition of the present invention is closely related to the types of each medicinal ingredient in the prescription.

[0074] The dried ginger in the formula is warm in nature and pungent in taste, entering the heart, lung, spleen, and stomach meridians. It can enhance the warming and invigorating effect of cinnamon twig on heart yang, targeting the core pathogenesis of 'heart yang deficiency' in patients with ischemic heart failure, relieving symptoms such as aversion to cold, cold limbs, and palpitations. Its synergistic effect with cinnamon twig significantly enhances the warming yang effect. Furthermore, Acanthopanax senticosus is warm in nature and pungent and slightly bitter in taste, entering the spleen, kidney, and heart meridians. It has the effects of invigorating qi and strengthening the spleen, tonifying the kidneys and calming the mind, and promoting blood circulation and unblocking collaterals. It can improve symptoms such as fatigue and shortness of breath caused by insufficient myocardial blood supply in patients. It also contains Acanthopanax senticosus saponins, which can protect myocardial cells and reduce ischemia. Reperfusion injury; *Polygonum hydropiper* is cold in nature and salty in taste, entering the liver and stomach meridians. It can invigorate blood circulation, eliminate masses, strengthen the spleen and promote diuresis. Targeting the symptoms of blood stasis and edema often accompanied by ischemic heart failure patients, it works synergistically with *Poria cocos* and *Atractylodes macrocephala* in the formula to promote diuresis and reduce swelling, while also improving myocardial microcirculation; *Verbena officinalis* is added to enhance the overall blood-activating and meridian-clearing power of the formula through its blood-activating, stasis-dispersing, and diuretic effects, promoting the dissipation of blood stasis and improving myocardial ischemia; *Cornus officinalis* is used to enhance the body's tolerance and reduce adverse drug reactions.

[0075] In summary, the traditional Chinese medicine composition of this invention exhibits good effects in improving cardiac function, reducing myocardial damage and inflammation, and regulating myocardial fibrosis. Furthermore, it possesses a multi-target, multi-pathway mechanism of action, providing strong experimental evidence for its clinical application in the treatment of heart diseases (such as ischemic heart failure and myocardial injury-related diseases). Future clinical research can further verify its efficacy and safety in humans, while also delving into its molecular mechanisms of action to provide more support for the modernization and precision treatment of heart diseases using traditional Chinese medicine. In addition, further exploration of the combined application of this traditional Chinese medicine composition with existing clinical drugs (such as ACEIs) can be undertaken to leverage synergistic effects and enhance therapeutic efficacy.

Claims

1. A traditional Chinese medicine composition for treating ischemic heart failure, characterized in that, This herbal composition is made from the following raw materials in parts by weight: 5-15 parts cinnamon twig, 5-15 parts atractylodes macrocephala, 5-15 parts poria cocos, 6-12 parts dried ginger, 5-15 parts eleutherococcus senticosus, 10-30 parts water lily seeds, 3-9 parts verbena, 6-12 parts cornus officinalis, and 3-9 parts prepared licorice root. In this herbal composition, cinnamon twig and dried ginger are the principal herbs, atractylodes macrocephala and poria cocos are the assistant herbs, eleutherococcus senticosus, verbena, water lily seeds, and cornus officinalis are the adjuvant herbs, and prepared licorice root is the guiding herb.

2. The traditional Chinese medicine composition for treating ischemic heart failure according to claim 1, characterized in that, It is made from the following raw materials in parts by weight: 10 parts cinnamon twig, 10 parts atractylodes macrocephala, 10 parts poria cocos, 9 parts dried ginger, 10 parts eleutherococcus senticosus, 15 parts water lily seeds, 6 parts verbena, 9 parts cornus officinalis, and 6 parts prepared licorice root.

3. The preparation method of the traditional Chinese medicine composition for treating ischemic heart failure according to any one of claims 1-2, characterized in that, Includes the following steps: Step 1: Weigh out each Chinese medicinal herb as raw material according to the prescription ratio; Step 2: Soak the herbs in 10-15 times their volume of water for 30-60 minutes, based on the amount of herbs taken in Step 1. Step 3: Boil the soaked herbs twice, filter the liquids separately, and combine them. Step 4: Concentrate the combined decoction to obtain a medicinal paste; Step 5: Further process the obtained liquid medicine to prepare the desired dosage form.

4. The method for preparing a traditional Chinese medicine composition for treating ischemic heart failure according to claim 3, characterized in that, The decoction method in step 3 is to first bring it to a boil over high heat, then simmer it over low heat for 60 minutes, and filter it to obtain the first decoction. After the decoction is completed, the liquid and the dregs are separated. The dregs are then added to 8 times the amount of water, brought to a boil over high heat, then simmered for 30 minutes, and filtered to obtain the second decoction. The filtered decoctions are then combined.

5. The method of claim 3, wherein the method is a method of preparing a traditional Chinese medicine composition for treating ischemic heart failure, characterized in that, The further processing in step 5 includes: obtaining dry powder or extract powder by vacuum concentration, spray drying or freeze drying.

6. The traditional Chinese medicine composition for treating ischemic heart failure according to claim 1 or 2, characterized in that, Dosage forms include: adding excipients, mixing, granulating or compressing to make granules or tablets; filling the resulting powder or granules into empty capsules to prepare capsules; sterilizing and dispensing the clarified drug solution to prepare oral liquids; or adding suitable binders to make water pills, honey pills or ointments.

Citation Information

Patent Citations

  • Tablets for warming phlegm and retained fluid and removing dampness through diuresis

    CN102988485A

  • Traditional Chinese medicine composition for treating chronic heart failure

    CN105311222A

  • Linggui zhugan decoction extract and preparation method thereof

    CN112294869A

  • Pharmaceutical composition as well as preparation method, preparation and application thereof

    CN113244308A

  • Traditional Chinese medicine composition for treating chronic heart failure and application thereof

    CN119970969A